Cargando…
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293614/ https://www.ncbi.nlm.nih.gov/pubmed/35032970 http://dx.doi.org/10.3350/cmh.2021.0287 |